Delivering better treatments for neglected patients
DNDi’s objective is to deliver 25 new treatments for neglected patients by 2028.
Since 2003, DNDi has worked with its worldwide network of partners to:
- develop two new chemical entities: fexinidazole, the first all-oral treatment for the two forms of sleeping sickness (T.b. gambiense and T.b. rhodesiense), and ravidasvir, a simple-to-use and affordable treatment for hepatitis C
- develop 10 new treatments from existing molecules and recombining drugs to bring better treatments to patients for malaria, Chagas disease, leishmaniasis, HIV-visceral leishmaniasis co-infection, and paediatric HIV
- initiate GARDP, a not-for-profit research and development organization developing and delivering new or improved antibiotic treatments
Treatments delivered
Fexinidazole for T.b. rhodesiense sleeping sickness
Safe and effective oral cure for acute form of sleeping sickness
Partnership with Sanofi and the HAT-r-ACC consortium
New recommendations for treating visceral leishmaniasis in Latin America
Liposomal amphotericin B recommended instead of pentavalent antimonials
Partnership with the University of Brasilia and the Oswaldo Cruz Foundation of Brazil.
‘4-in-1’ antiretroviral treatment
Child-friendly treatment specifically designed for infants and young children with HIV
Partnership with Cipla Limited
New treatments for HIV/VL
Better treatments for people living with both HIV and visceral leishmaniasis
Partnership with Médecins Sans Frontières and other partners.
An affordable hepatitis C cure to leave no one behind
An affordable hepatitis C cure to leave no one behind
Partnership with Ministries of Health of Malaysia and Thailand, Pharmaniaga, Pharco Pharmaceuticals, and Médecins Sans Frontières France.
Fexinidazole
First all-oral cure for all stages of sleeping sickness
Partnership with Sanofi, the Human African Trypanosomiasis Platform, Médecins Sans Frontières, national control programmes, and WHO.
GARDP
Incubation of the Global Antibiotic Research & Development Partnership (GARDP) to address antimicrobial resistance
Partnership with WHO
Super-booster therapy
More effective treatment for children with HIV and TB
Partnership with the Department of Health, South Africa
New visceral leishmaniasis treatments in South Asia
Better treatments in South Asia
Partnerships with kala-azar actors in South Asia including ministries of health, research institutes, NGOs, and WHO-TDR.
Paediatric benznidazole
First paediatric drug for Chagas disease
Partnership with LAFEPE (Brazil) to develop the first paediatric treatment for Chagas (2011); subsequent partnerships with Chemo Research, Exeltis USA, Mundo Sano Foundation, and Laboratorio ELEA PHOENIX.
SSG&PM
Cheaper, more effective visceral leishmaniasis treatment in Africa
Partnership with the Leishmaniasis East Africa Platform (LEAP), national control programmes, Médecins Sans Frontières, and WHO.
Nifurtimox-eflornithine combination therapy (NECT)
Better, safer treatment for sleeping sickness
Partnership with Médecins Sans Frontières, Epicentre, national control programmes, and WHO.
ASMQ*
Fixed-dose combination of artesunate and mefloquine for malaria
Partnership with Farmanguinhos/Fiocruz (Brazil) and Cipla (India)
*Project handed over to Medicines for Malaria Venture in 2015
ASAQ*
Fixed-dose combination of artesunate and amodiaquine to treat malaria
Partnership with Sanofi
*Project handed over to Medicines for Malaria Venture in 2015
Help neglected patients
To date, we have delivered thirteen new treatments, saving millions of lives.
Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there.
